Sugi Predict

Sugi Predict / Compounds / SCHEMBL1161526

SCHEMBL1161526

SCHEMBL1161526

Fc1cc2ncccc2c(F)c1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.43
▸ MAPT P10636 3/20 0.43
▸ NR4A2 P43354 1/20 0.40
▸ HTT P42858 4/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ MPI P34949 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ MET P08581 6/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ HSP90AA1 P07900 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ TP53 P04637 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ LMNA P02545 2/20 0.35
▸ HSP90AB1 P08238 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28724331 0.82 L3MBTL1 (0.41) KDM4EMAPTNR4A2HTTCYP1A2
SCHEMBL29360805 0.82 KDM4E (0.41) KDM4EMAPTNR4A2HTTCYP1A2
SCHEMBL29363534 0.82 L3MBTL1 (0.41) KDM4EMAPTNR4A2HTTCYP1A2
SCHEMBL28724330 0.82 KDM4E (0.41) KDM4EMAPTNR4A2HTTCYP1A2
SCHEMBL24937074 0.78 NR4A2 (0.47) KDM4EMAPTNR4A2HTTMPI
SCHEMBL12877851 0.78 KDM4E (0.43) KDM4EMAPTNR4A2HTTMPI
SCHEMBL12121755 0.78 L3MBTL1 (0.44) KDM4EMAPTNR4A2CYP1A2MPI
SCHEMBL13692759 0.78 KDM4E (0.43) KDM4EMAPTNR4A2HTTCYP1A2
SCHEMBL28864789 0.77 MET (0.42) KDM4EMAPTNR4A2MPIL3MBTL1
SCHEMBL29870124 0.77 MET (0.42) KDM4EMAPTNR4A2MPIL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067655-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. 2024-02-29 — — US disclosed
EP-4304727-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2024-01-17 — — EP disclosed
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-12-12 — — US disclosed
EP-4243816-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2023-09-20 — — EP disclosed
US-20230019732-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-01-19 — — US disclosed
CN-107312009-B Quinoline compound, preparation method, intermediate, pharmaceutical composition and application thereof 上海医药集团股份有限公司 2022-09-20 — — CN disclosed
WO-2022192431-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2022-09-15 — — WO disclosed
WO-2022104206-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2022-05-19 — — WO disclosed
EP-3625228-B1 PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2021-07-07 — — EP disclosed
US-20210113559-A1 PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2021-04-22 — — US disclosed
EP-2162132-A1 HETEROCYCLIC KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2010-03-17 — — EP disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US disclosed
WO-2009106577-A1 IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE NOVARTIS AG (CH) 2009-09-03 — — WO disclosed
WO-2009106577-A1 IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE NOVARTIS AG (CH) 2009-09-03 — — WO disclosed
EP-2081937-A2 TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-07-29 — — EP disclosed
US-20090156594-A1 HETEROCYCLIC KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-06-18 — — US disclosed
WO-2008144767-A1 HETEROCYCLIC KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-11-27 — — WO disclosed
WO-2008051805-A2 TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES MET, ERBB2, ALK KDM4E 649/4885MAPT 2330/4885NR4A2 2353/4885
US-20240067655-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, NUAK1, NUAK2 KDM4E 2161/4885MAPT 596/4885NR4A2 1255/4885
US-20230019732-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 KDM4E 3952/4885MAPT 3009/4885NR4A2 3450/4885
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 KDM4E 1571/4885MAPT 4627/4885NR4A2 57/4885
US-20210113559-A1 PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 KDM4E 1571/4885MAPT 4627/4885NR4A2 57/4885
US-20090156594-A1 HETEROCYCLIC KINASE MODULATORS MAP3K20, MAP4K2, MAP3K13 KDM4E 992/4885MAPT 2253/4885NR4A2 2518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.